Energy -
Oil & Gas Midstream - NYSE - US
$ 47.43
-3.24 %
$ 1.6 B
Market Cap
19.68
P/E
1. INTRINSIC VALUE
Balance Sheet
Global Partners LP
| Current Assets | 1.21 B |
| Cash & Short-Term Investments | 8.21 M |
| Receivables | 473 M |
| Other Current Assets | 727 M |
| Non-Current Assets | 2.58 B |
| Long-Term Investments | 92.7 M |
| PP&E | 2.01 B |
| Other Non-Current Assets | 479 M |
| Current Liabilities | 1 B |
| Accounts Payable | 510 M |
| Short-Term Debt | 56.8 M |
| Other Current Liabilities | 433 M |
| Non-Current Liabilities | 2.07 B |
| Long-Term Debt | 1.45 B |
| Other Non-Current Liabilities | 618 M |
EFFICIENCY
Earnings Waterfall
Global Partners LP
| Revenue | 17.2 B |
| Cost Of Revenue | 16.1 B |
| Gross Profit | 1.06 B |
| Operating Expenses | 807 M |
| Operating Income | 251 M |
| Other Expenses | 141 M |
| Net Income | 110 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Global Partners LP
| Net Income | 110 M |
| Depreciation & Amortization | 140 M |
| Capital Expenditures | -103 M |
| Stock-Based Compensation | 15.5 M |
| Change in Working Capital | -230 M |
| Others | 31.4 M |
| Free Cash Flow | -71.7 M |
Wall Street Analysts Price Targets
Global Partners LP
GLP has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
1.94%
DIVIDEND YIELD
0.74 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Global Partners LP
Sold
0-3 MONTHS
794 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
532 K USD 1
0-3 MONTHS
3.01 M USD 1
3-6 MONTHS
3.48 M USD 1
6-9 MONTHS
7.9 M USD 1
9-12 MONTHS
7. News
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ”) underway in Australia.
thenewswire.com
- 2 weeks ago
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Enrollment of patients for all 5 Study arms has now been completed on schedule.
accessnewswire.com
- 2 weeks ago
Lexaria's Human GLP-1 Study #5 Begins Dosing
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.
accessnewswire.com
- 2 weeks ago
Labor Smart Targets GLP-1 Market with Functional Gummies - Pre-Orders Begin April 7th
JACKSON, WY / ACCESS Newswire / April 1, 2025 / Labor Smart, Inc. (OTC PINK:LTNC), through its newest subsidiary Elevate Health and Wellness Nutritionals, is entering the fast-growing GLP-1 weight loss space with the launch of a specialized line of GLP-1 Support Gummies. Pre-orders for the new product line will officially begin Monday, April 7, 2025.
accessnewswire.com
- 2 weeks ago
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study.
globenewswire.com
- 2 weeks ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
globenewswire.com
- 2 weeks ago
The Vitamin Shoppe® Unveils First-of-its-Kind Supplement Line Formulated for GLP-1 Users
The d ietitian formulated, doctor-approved GLP-1 Support from Whole Health Rx™ by The Vitamin Shoppe® range of supplements delivers comprehensive nutritional solutions for individuals on GLP-1 weight-loss medications SECAUCUS, N.J. , March 31, 2025 /PRNewswire/ -- The Vitamin Shoppe®, a leading omni-channel specialty retailer of nutritional products, today announced the launch of GLP-1 Support from Whole Health Rx™ by The Vitamin Shoppe®, an innovative line of dietary supplements designed to address the unique health and nutritional needs of individuals using GLP-1 medications for weight management.
prnewswire.com
- 2 weeks ago
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Comp.
businesswire.com
- 2 weeks ago
Own The Gas Pump, And Collect 8% Yields
I love topping off my gas tank; I get to see all the people who pay for my retirement in action. Sometimes, it's the most overlooked aspects of life that can pay you the most income! My Income Method is designed to drive massive sums of income from the market to your account.
seekingalpha.com
- 3 weeks ago
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Novo Nordisk sinking on lighter-than-expected GLP-1 demand.
youtube.com
- 3 weeks ago
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes.
fool.com
- 3 weeks ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
globenewswire.com
- 3 weeks ago
8. Profile
Summary
Global Partners LP GLP
COUNTRY
US
INDUSTRY
Oil & Gas Midstream
MARKET CAP
$ 1.6 B
Dividend Yield
1.94%
Description
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers in the New England states, Mid-Atlantic region, and New York. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-continent region of the United States and Canada. Its Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. It also aggregates crude oil through truck or pipeline in the mid-continent region of the United States and Canada, as well as transports it through rail and ships it through barge to refiners. The company's Gasoline Distribution and Station Operations segment sells branded and unbranded gasoline to gasoline station operators and sub-jobbers; operates gasoline stations and convenience stores; and provides car wash, lottery, and ATM services, as well as leases gasoline stations. Its Commercial segment sells and delivers unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to customers in the public sector, as well as to commercial and industrial end-users; and sells custom blended fuels. As of December 31, 2021, the company had a portfolio of 1,595 owned, leased, and supplied gasoline stations, which included 295 directly operated convenience stores; and owned, leased, or maintained storage facilities at 26 bulk terminals with a collective storage capacity of 11.9 million barrels. Global GP LLC serves as the general partner of the company. The company was incorporated in 2005 and is based in Waltham, Massachusetts.
Contact
800 South Street, Waltham, MA, 02454-9161
https://www.globalp.com
IPO
Date
Sept. 29, 2005
Employees
3300
Officers
Philip Segaloff
Senior Associate General Counsel
Mr. Scott Solomon
Senior Vice President of Investor Relations
Mr. Matthew Spencer
Chief Accounting Officer of Global GP LLC
Mr. Sean T. Geary
Chief Legal Officer & Secretary
Mr. Gregory B. Hanson
Chief Financial Officer of Global GP LLC
Catie Kerns
Senior Vice President of Corporate Affairs and Sustainability & VP of Communications
Ms. Maura McDonough
Chief People Officer
Mr. Eric S. Slifka
President, Chief Executive Officer & Vice Chairman of Global GP LLC
Ms. Lorraine Spadaro
Chief Information Officer of Global GP LLC
Mr. Mark A. Romaine
Chief Operating Officer of Global GP LLC